X4 Pharmaceuticals Announces Strategic Restructuring to Drive Value and Maximize Opportunity for Mavorixafor in Chronic Neutropenia
Provided By GlobeNewswire
Last update: Feb 6, 2025
Full enrollment in ongoing global, pivotal Phase 3 clinical trial in chronic neutropenia
on track for mid-2025
Right-sizing commercial efforts to optimize XOLREMDI promotion and
support U.S. WHIM syndrome community
3.725
-0.02 (-0.67%)
Find more stocks in the Stock Screener
XFOR Latest News and Analysis
9 days ago - ChartmillStay updated with the stocks that are on the move in today's pre-market session.Before the opening bell on Thursday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.
